DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on March 2, 2005; DOI: 10.1124/dmd.105.003681


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.003681v1
33/5/689    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Picard, N.
Right arrow Articles by Marquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Picard, N.
Right arrow Articles by Marquet, P.


Received for publication January 12, 2005.
Revised February 16, 2005.
Accepted for publication February 17, 2005.

IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS

Nicolas Picard 1, Thierry Cresteil 2, Nassim Djebli 3, Pierre Marquet 4*

1 Department of Pharmacology and Toxicology, University Hospital Limoges 2 ICSN - CNRS 3 Laboratory of Medical Pharmacology, University of Limoges 4 CHU Dupuytren

* Address correspondence to: E-mail: marquet{at}unilim.fr

Abstract

Buprenorphine (BUP) is a synthetic derivative of the morphine alkaloid thebaine. BUP is metabolized by N-dealkylation to form the active metabolite nor-buprenorphine (Nor-BUP) and both undergo subsequent glucuronidation. Although BUP has been used clinically for years, its metabolism has still not been fully elucidated. The aim of this study was to clarify the identity of the human hepatic cytochromes P450 (CYP) involved in BUP metabolism and to investigate other potential metabolites. The metabolism of BUP was examined using human liver microsomes (HLM), Ad 293 CYP transfected cell lines as well as CYP 3A4 and 2C8 recombinant isoforms. The kinetic parameters of metabolites formation were calculated for HLM and competent isoforms. Individual contribution of CYP isoforms in BUP metabolism as well as Nor-BUP production was evaluated using chemical inhibition experiments, as well as the relative activity factor (RAF) approach. The analytical method used was based on liquid chromatography-mass spectrometry. Among the 13 CYP isoforms tested, CYP 3A4, 2C8, 3A5 and 3A7 produced Nor-BUP. Based on the results of chemical inhibition, CYP 3A4 accounts for about 65 % of Nor-BUP production and CYP 2C8 for about 30 %. BUP utilization by either HLM or CYP transfected cells revealed that another oxidative metabolic pathway exists, which was found to involve CYP 2C9, 2C18, 2C19 and mainly CYP 3A. Incubation of BUP or Nor-BUP with HLM led to the formation of new metabolites, identified by tandem mass spectrometry as being hydroxy-BUP and hydroxy-Nor-BUP. Hydroxy-BUP was produced by the CYP3A, but not the 2C isoforms.


Key words: cytochrome P450 catalyzed oxidations, human CYP enzymes, in vitro-in vivo prediction, metabolite identification, metabolite kinetics, microsomes





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.